Skip to main content

Advertisement

SpringerLink
Log in

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

We conducted a prospective study to investigate the role of four single nucleotide polymorphisms (SNPs) of XPG on the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with platinum-based doublets chemotherapy. In total, 277 patients with histologically confirmed NSCLC were mainly from December 2007 and December 2008. The genotypes of rs2296147T > C, rs1047768C > T, rs873601G > A, and rs17655G > C were determined by polymerase chain reaction-restriction fragment length polymorphism. By univariate analysis, a shorter survival was associated with older age, sex, and higher disease stage. By multivariate Cox regression analysis, patients carrying rs2296147 TT genotype and T allele were prognostic factors of progression-free survival (PFS) and overall survival (OS). Similarly, patients carrying rs873601 GG genotype and G allele were marginally significantly associated with favorable outcome for PFS and OS. We found that individuals carrying both rs2296147 T allele and rs873601 G allele were associated with better PFS and OS. However, rs1047768C > T and rs17655G > C polymorphisms did not influence the PFS and OS of advanced NSCLC. In summary, our study provided statistical evidence that XPG rs2296147T > C and rs873601G > A polymorphisms may be used as surrogate markers toward individualizing NSCLC treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. International Agency for Research on Cancer. Lung cancer estimated incidence, Mortality and Prevalence Worldwide in 2012. 2012. http://globocan.iarc.fr/factsheet.asp. Access in: 2014-2-1.

  2. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Interv Radiol. 2013;30(2):93–8.

    Article  Google Scholar 

  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  4. Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, et al. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):222–30.

    Article  CAS  PubMed  Google Scholar 

  5. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian trials in medical oncology study. Ann Oncol. 2007;18(3):461–7.

    Article  CAS  PubMed  Google Scholar 

  6. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131–9.

    Article  PubMed  Google Scholar 

  7. Johnson SW, Stevenson JP, O’Dwyer PJ. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 376–88.

    Google Scholar 

  8. Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2011;73(1):110–5.

    Article  PubMed  Google Scholar 

  9. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst. 2000;92(6):440–1.

    Article  CAS  PubMed  Google Scholar 

  10. He C, Duan Z, Li P, Xu Q, Yuan Y. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs. 2013;24(3):300–5.

    Article  CAS  PubMed  Google Scholar 

  11. Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, et al. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer. 2012;118(3):689–97.

    Article  CAS  PubMed  Google Scholar 

  12. Melis JP, van Steeg H, Luijten M. Oxidative DNA damage and nucleotide excision repair. Antioxid Redox Signal. 2013;18(18):2409–19.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wen H, Feng CC, Fang ZJ, Xia GW, Jiang HW, Xu G, et al. Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers. Actas Urol Esp. 2013;37(5):259–65.

    Article  CAS  PubMed  Google Scholar 

  14. Peng Q, Lao X, Li R, Qin X, Li S. Methodological remarks concerning a recent meta-analysis on XPG Asp1104His and XPF Arg415Gln polymorphisms and breast cancer risk. Breast Cancer Res Treat. 2013;139(2):617–8.

    Article  PubMed  Google Scholar 

  15. Yuan H, Li H, Ma H, Niu Y, Wu Y, Zhang S, et al. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. Exp Ther Med. 2012;3(4):719–24.

    PubMed Central  CAS  PubMed  Google Scholar 

  16. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer. 2009;65(2):230–6.

    Article  PubMed  Google Scholar 

  17. Butkiewicz D, Rusin M, Sikora B, Lach A, Chorąży M. An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep. 2010;38(8):5231–41.

    Article  PubMed  Google Scholar 

  18. Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC, et al. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. Asian Pac J Cancer Prev. 2013;14(2):701–5.

    Article  PubMed  Google Scholar 

  19. Yuli Y, Zhe S, Xia W, Siqing L, Zhenxuan W, Yu-Hua Z, et al. XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer. Pak J Med Sci. 2013;29(3):762–7.

    PubMed Central  PubMed  Google Scholar 

  20. Li XD, Han JC, Zhang YJ, Li HB, Wu XY. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev. 2013;14(1):145–8.

    Article  PubMed  Google Scholar 

  21. Caiola E, Porcu L, Fruscio R, Giuliani D, Milani R, Torri V, et al. DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics J. 2013;13(2):159–72.

    Article  CAS  PubMed  Google Scholar 

  22. Biason P, Hattinger CM, Innocenti F, Talamini R, Alberghini M, Scotlandi K, et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J. 2012;12(6):476–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Schrama D, Scherer D, Schneider M, Zapatka M, Bröcker EB, Schadendorf D, et al. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. J Invest Dermatol. 2011;131(6):1280–90.

    Article  CAS  PubMed  Google Scholar 

  24. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18(9):2688–98.

    Article  PubMed  Google Scholar 

  25. Sakano S, Hinoda Y, Sasaki M, Wada T, Matsumoto H, Eguchi S, et al. Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics. 2010;11(10):1377–87.

    Article  CAS  PubMed  Google Scholar 

  26. Butkiewicz D, Rusin M, Sikora B, Lach A, Chorąży M. An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep. 2011;38(8):5231–41.

    Article  CAS  PubMed  Google Scholar 

  27. Staresincic L, Fagbemi AF, Enzlin JH, Gourdin AM, Wijgers N, Dunand-Sauthier I, et al. Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J. 2009;28(8):1111–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33:565–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The authors would like to thank the Henan Provincial People's Hospital for providing help as well as patients who provided blood samples for our study.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Henan Provincial People’s Hospital, Zhengzhou, China

    Weicai Hu, Pu Zhao & Guangyu Yang

  2. Department of Respiratory Medicine, Henan Provincial People’s Hospital, Zhengzhou, China

    Jinbing Pan

  3. Department of Health of Social Behavior, West China School of Public Health, Sichuan University, Chengdu, China

    Shujuan Yang

Authors
  1. Weicai Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinbing Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guangyu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shujuan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinbing Pan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, W., Pan, J., Zhao, P. et al. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer. Tumor Biol. 35, 5561–5567 (2014). https://doi.org/10.1007/s13277-014-1732-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1732-4

Keywords

Search

Navigation